.jpeg)
奥密克戎正以前所未有速度传播，辉瑞新口服药对其有效！
The novel coronavirus pneumonia (COVID-19), referred to as "COVID-19", has seriously endangered human health and life safety since the outbreak. In particular, its "fickleness" has posed a huge threat to us. Every mutation accelerates the spread of the epidemic. Currently, the mutant strain Omicron (English name: Omicron, code: B.1.1.529) is spreading at an unprecedented speed. Pfizer announced that its new coronavirus oral drug Paxlovid is effective against the Omicron mutant strain.
Source: pexels
The current communication situation of Omicron
On December 14, 2021, the World Health Organization (WHO) held a press conference on the new crown epidemic. WHO Director-General Tedros Adhanom Ghebreyesus stated that Omicron is spreading faster than any variant in the past. Currently, 77 countries and regions have reported the Omicron variant. Although the variant has not yet been detected in some countries and regions, it is likely to have spread to most countries and regions around the world - we have underestimated the harm of the Omicron variant.
Although the symptoms of infection with the Omicron variant are not severe, if a large number of infection cases occur, it will impose an unbearable burden on the global health system. Tedros emphasized that COVID-19 vaccines alone cannot fully protect people of all countries from being infected by Omicron. Wearing masks and maintaining social distance remain the top priorities in preventing and controlling the epidemic.
An oral drug for COVID-19 developed by PfizerPaxlovid
On the 14th, the US pharmaceutical company Pfizer announced the test data of Paxlovid, an oral drug for COVID-19. Pfizer said that the drug can reduce hospitalization and mortality of adult patients in high-risk groups by 89%, and is effective against the new variant of the virus Omicron.
The study enrolled more than 2,200 people in high-risk groups who had not received the new coronavirus vaccine. The subjects took medicine every 12 hours. The results found that if the patients took Paxlovid within three days of the onset of symptoms, they could reduce hospitalization or mortality by 89%; if patients took Paxlovid within five days of the onset of symptoms, they could also reduce hospitalization or mortality by 88%.
By day 28 of the trial, 0.7% (5/697) of patients in the Paxlovid group were hospitalized, compared with 6.5% (44/682) of patients in the placebo group. There were no deaths among those who took the oral drug Paxlovid, compared with 12 deaths in a control group who did not take the oral drug.
The Omicron is coming, what should we do?
Wearing a mask remains an effective way to prevent the spread of the virus, and it also applies to the Omicron variant. Even if you have been fully vaccinated against COVID-19 and a booster shot, you must wear a mask in indoor public places, public transportation and other crowded places. In addition, wash hands frequently and ventilate the room well.
Do a good job in personal health monitoring. If symptoms similar to COVID-19 occur, such as fever, cough, shortness of breath, etc., you should monitor your body temperature in time and seek medical advice.
Reduce unnecessary entry and exit. In a short period of time, many countries and regions have successively reported the importation of the Omicron variant, and the current global understanding of this variant is still limited. Therefore, travel to high-risk areas should be minimized and personal protection during travel should be strengthened to reduce the chance of infection with the Omicron variant.
Reduce unnecessary entry and exit. At present, 77 countries and regions have reported the importation of the Omicron variant, and our understanding of this variant is still limited. Therefore, we should reduce travel to high-risk areas, strengthen personal protection during travel, and reduce the chance of infection with the Omicron variant.
References
https://baijiahao.baidu.com/s?id=1719144797558005965&wfr=spider&for=pc
https://baijiahao.baidu.com/s?id=1719188243268266007&wfr=spider&for=pc
https://www.163.com/dy/article/GR910D7L05504DOQ.html
https://weibo.com/2656274875/L66XwhTf0?refer_flag=1001030103_
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
